Welcome to our dedicated page for Renovorx SEC filings (Ticker: RNXT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The RenovoRx, Inc. (RNXT) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, including current reports, registration statements, and other documents filed with the U.S. Securities and Exchange Commission. RenovoRx is a life sciences company developing targeted oncology therapies and commercializing RenovoCath®, an FDA‑cleared local drug‑delivery device enabled by its patented Trans‑Arterial Micro‑Perfusion (TAMP™) therapy platform.
Through its SEC filings, RenovoRx reports financial results, commercialization progress for RenovoCath, and updates on its clinical development programs. For example, Form 8‑K filings have referenced quarterly financial press releases that discuss revenue from RenovoCath sales, expansion of cancer center customers, and advancement of the Phase III TIGeR‑PaC trial evaluating intra‑arterial gemcitabine (IAG) delivered via RenovoCath in locally advanced pancreatic cancer.
Filings also describe capital markets activity. In a Form 8‑K dated November 14, 2025, RenovoRx reported entering into a Capital on Demand™ Sales Agreement with a sales agent, allowing the company to issue and sell shares of common stock in at‑the‑market offerings or negotiated transactions under an effective shelf registration statement on Form S‑3. Related exhibits include the sales agreement and a legal opinion on the validity of the shares.
On Stock Titan, users can review these filings alongside AI‑generated highlights that help explain key sections, such as risk factor updates, financing terms, and business strategy disclosures. Investors can also monitor current reports that incorporate press releases detailing clinical milestones, registry studies, Scientific Advisory Board changes, and commercialization strategy for RenovoCath and the TAMP platform.
In addition, this page is a starting point for tracking RenovoRx’s ongoing reporting obligations, including future quarterly and annual reports, as well as any additional Forms 8‑K that may discuss clinical trial developments, capital raises, or changes in governance.
RenovoRx reported full-year 2025 results and a business update. Revenue rose to $1.1 million from $43,000 in 2024, reflecting the first full year of RenovoCath commercialization across U.S. cancer centers. Net loss widened to $11.2 million from $8.8 million as the company invested in its Phase III TIGeR-PaC trial and commercial buildout.
Cash and cash equivalents were $7.0 million at December 31, 2025, and an oversubscribed March 2026 private placement added $10 million in gross proceeds, leaving about $13 million on hand. As of March 24, 2026, the TIGeR-PaC trial had randomized 104 patients with 72 events toward a 114-patient, 86-event target, and 12 cancer centers were actively using RenovoCath with additional centers in the pipeline.
RenovoRx, Inc. reports its annual results and business progress for the year ended December 31, 2025. The company generated $1.1 million in revenue from U.S. sales of its FDA‑cleared RenovoCath device, used for targeted intra‑arterial drug delivery in cancer care.
RenovoCath adoption is expanding, with 12 U.S. cancer centers using the device and a total of 33 centers requesting access, supported by more than 700 clinical procedures to date. RenovoRx is also advancing its TAMP therapy platform and IAG drug–device combination in the Phase III TIGeR‑PaC trial for locally advanced pancreatic cancer, where an initial interim analysis showed a 6‑month median overall survival benefit and over 65% fewer adverse events versus standard intravenous chemotherapy, leading the independent Data Monitoring Committee to recommend continuation.
VOLL MARK reported acquisition or exercise transactions in this Form 4 filing.
RenovoRx, Inc. chief financial officer Mark Voll reported an equity grant of 12,380 shares of common stock. These shares were granted as restricted stock units for his service as a consultant of the company for January 2026 and carry a stated price of $0.00 per share.
Following this grant, Voll directly holds 37,380 shares of common stock and has an additional 97,200 shares reported as indirectly held through the Voll Family Trust DTD 6/23/2010, with Mark Voll as trustee. This filing reflects compensation rather than an open-market stock purchase.
RenovoRx, Inc. filed an amended initial ownership report showing that Chief Financial Officer Mark Voll beneficially owns 25,000 shares of the company’s common stock. These shares are held directly and, according to a footnote, were purchased in open‑market transactions before he became CFO.
RenovoRx, Inc. appointed Ramtin Agah, M.D., its Chief Medical Officer and Board Chairman, to the newly created role of Executive Chairman, effective February 27, 2026. An offer letter dated March 24, 2026 sets his annualized base salary at $450,000 for at least 30 hours per week.
Dr. Agah is eligible for a discretionary annual bonus of up to 40% of his base salary, with the first bonus payable in 2027 for 2026 performance. He may also receive annual stock options and other equity awards under the 2021 Omnibus Equity Incentive Plan, subject to vesting and continued service. His employment is at will and includes customary confidentiality and intellectual property provisions.
RenovoRx director Marton Laurence, through his Laurence Marton Rollover IRA, bought securities in a private placement. The IRA acquired 4,860 warrants and 9,720 shares of RenovoRx common stock for an aggregate purchase price of $10,000.
The warrants are immediately exercisable at $1.9326 per share and will expire on the earlier of March 30, 2029 or 30 days after RenovoRx reports at least $1.5 million in product sales revenue for any calendar quarter in a quarterly or annual report.
RenovoRx, Inc. director and CEO Shaun Bagai reported indirect purchases through The Bagai Family Trust on March 20, 2026. The trust bought 24,300 shares of common stock and 12,150 warrants in a private placement for an aggregate of $25,000.
After these transactions, the trust holds 313,357 shares of common stock and 12,150 warrants, while Bagai also holds 50,983 shares directly. The warrants are exercisable immediately and can be converted into 12,150 shares of common stock at an exercise price of $1.9326 per share.
The warrants expire on the earlier of March 30, 2029 or 30 days after RenovoRx reports at least $1.5 million in product sales revenue for any calendar quarter in a quarterly or annual report.
RenovoRx, Inc. Chief Financial Officer Mark Voll, through the Voll Family Trust, reported buying both common stock and warrants in a private placement. The trust acquired 97,200 shares of common stock and 48,600 warrants, for an aggregate purchase price of $100,000.
The warrants are exercisable immediately at $1.9326 per share of underlying common stock and will expire on the earlier of March 30, 2029 or 30 days after RenovoRx reports at least $1.5 million in product sales revenue for any calendar quarter.
RenovoRx, Inc. filed an initial ownership report for company executive Mark Voll. The filing shows he directly holds 25,000 shares of RenovoRx common stock. A footnote explains these securities were purchased in open-market transactions before his appointment to a senior executive role at the company.
RenovoRx, Inc. entered into a private placement with 15 accredited and institutional investors, including company insiders, raising approximately $10 million in gross proceeds. The company sold 8,438,790 shares of common stock, pre-funded warrants for 2,200,000 shares, and revenue milestone warrants for 5,319,392 shares.
Institutional investors paid $0.938 per share and related milestone warrant, while insiders paid $1.0288 to comply with Nasdaq rules. The milestone warrants are immediately exercisable at $1.751 per share for institutions and $1.9326 for insiders, and expire on the earlier of March 30, 2029 or 30 days after RenovoRx reports at least $1.5 million in product sales revenue for a quarter.
RenovoRx agreed to file and seek effectiveness of a resale registration statement for the shares and warrant shares within specified timelines, with cash liquidated damages of up to 10% of each investor’s subscription amount if deadlines are missed. The company plans to use proceeds to support commercialization of its RenovoCath device and advance its Phase III TIGeR-PaC trial.